SI21256A - Stabilizacija profila sproščanja učinkovin iz formulacije - Google Patents

Stabilizacija profila sproščanja učinkovin iz formulacije Download PDF

Info

Publication number
SI21256A
SI21256A SI200200179A SI200200179A SI21256A SI 21256 A SI21256 A SI 21256A SI 200200179 A SI200200179 A SI 200200179A SI 200200179 A SI200200179 A SI 200200179A SI 21256 A SI21256 A SI 21256A
Authority
SI
Slovenia
Prior art keywords
active substance
physical pretreatment
active ingredient
clarithromycin
pretreatment
Prior art date
Application number
SI200200179A
Other languages
English (en)
Slovenian (sl)
Inventor
Aleksander Resman
Temeljotov Darja Ferčej
Vlasta Humar
Marko Opresnik
Original Assignee
LEK farmacevtska družba d.d.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/521,295 priority Critical patent/US20060083759A1/en
Application filed by LEK farmacevtska družba d.d. filed Critical LEK farmacevtska družba d.d.
Priority to SI200200179A priority patent/SI21256A/sl
Priority to RU2005104423/15A priority patent/RU2354387C2/ru
Priority to AU2003248615A priority patent/AU2003248615B2/en
Priority to EP03764288A priority patent/EP1524965A2/en
Priority to YUP-2005/0038A priority patent/RS20050038A/sr
Priority to UAA200500254A priority patent/UA89020C2/ru
Priority to PL03372771A priority patent/PL372771A1/xx
Priority to PCT/SI2003/000025 priority patent/WO2004006888A2/en
Publication of SI21256A publication Critical patent/SI21256A/sl
Priority to HR20050040A priority patent/HRP20050040A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
SI200200179A 2002-07-17 2002-07-17 Stabilizacija profila sproščanja učinkovin iz formulacije SI21256A (sl)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US10/521,295 US20060083759A1 (en) 2002-07-17 2002-07-15 Stabilization of the profile of release of active substances from a formulation
SI200200179A SI21256A (sl) 2002-07-17 2002-07-17 Stabilizacija profila sproščanja učinkovin iz formulacije
RU2005104423/15A RU2354387C2 (ru) 2002-07-17 2003-07-15 Стабилизация профиля высвобождения активного вещества из лекарственной формы
AU2003248615A AU2003248615B2 (en) 2002-07-17 2003-07-15 Stabilization of the profile of release of active substances from a formulation
EP03764288A EP1524965A2 (en) 2002-07-17 2003-07-15 Stabilization of the profile of release of active substances from a formulation
YUP-2005/0038A RS20050038A (en) 2002-07-17 2003-07-15 Stabilization of the profile of release of active substances from a formulation
UAA200500254A UA89020C2 (ru) 2002-07-17 2003-07-15 Способ изготовления ядра таблетки кларитромицина, ядро и фармацевтическая композиция
PL03372771A PL372771A1 (en) 2002-07-17 2003-07-15 Stabilization of the profile of release of active substances from a formulation
PCT/SI2003/000025 WO2004006888A2 (en) 2002-07-17 2003-07-15 Stabilization of the profile of release of active substances from a formulation
HR20050040A HRP20050040A2 (en) 2002-07-17 2005-01-14 Stabilization of the profile of release of active supstances from a formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200200179A SI21256A (sl) 2002-07-17 2002-07-17 Stabilizacija profila sproščanja učinkovin iz formulacije

Publications (1)

Publication Number Publication Date
SI21256A true SI21256A (sl) 2004-02-29

Family

ID=30113493

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200200179A SI21256A (sl) 2002-07-17 2002-07-17 Stabilizacija profila sproščanja učinkovin iz formulacije

Country Status (10)

Country Link
US (1) US20060083759A1 (ru)
EP (1) EP1524965A2 (ru)
AU (1) AU2003248615B2 (ru)
HR (1) HRP20050040A2 (ru)
PL (1) PL372771A1 (ru)
RS (1) RS20050038A (ru)
RU (1) RU2354387C2 (ru)
SI (1) SI21256A (ru)
UA (1) UA89020C2 (ru)
WO (1) WO2004006888A2 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2283824B1 (en) * 2009-07-30 2017-04-19 Special Products Line S.p.A. Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin
CN108853039B (zh) * 2018-08-07 2021-03-09 河北君临药业有限公司 一种克拉霉素分散片及其生产工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1236023A (en) * 1984-07-18 1988-05-03 Yegnaswami Raghunathan Controlled release pharmaceutical preparations
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
CA2039742A1 (en) * 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials
US5599556A (en) * 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
US5919489A (en) * 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
SI20150A (sl) * 1999-02-19 2000-08-31 Lek, Tovarna Farmacevtskih In Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina
RU2230748C2 (ru) * 2000-03-15 2004-06-20 Ханми Фарм. Ко., Лтд. Способ получения кларитромицина в виде кристаллов формы ii
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system

Also Published As

Publication number Publication date
HRP20050040A2 (en) 2006-11-30
RS20050038A (en) 2007-06-04
EP1524965A2 (en) 2005-04-27
WO2004006888A3 (en) 2004-04-29
AU2003248615B2 (en) 2006-11-16
WO2004006888A2 (en) 2004-01-22
RU2354387C2 (ru) 2009-05-10
UA89020C2 (ru) 2009-12-25
RU2005104423A (ru) 2006-01-27
PL372771A1 (en) 2005-08-08
US20060083759A1 (en) 2006-04-20
AU2003248615A1 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
AU782282B2 (en) Pharmaceutical composition containing fenofibrate and preparation method
AU2002325192B2 (en) Controlled agglomeration
KR100958045B1 (ko) 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)페놀을 함유하고활성 성분의 방출이 지연되는 약제
EP2349336B1 (en) Mesoporous material excipients for poorly aqueous soluble ingredients
EP2436377B1 (en) Microspheres with improved bioavailability containing poorly water-soluble drugs, and method for preparing same
US20020009496A1 (en) Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
EP1722821B1 (en) Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same
CA3019257A1 (en) A pharmaceutical formulation of palbociclib and a preparation method thereof
EP3437646A1 (en) Oral preparation having exceptional elutability
WO2010133611A1 (en) Solid drug dispersions
EP1929997A1 (en) Oxcarbazepine formulations
EP2665466B1 (en) Solid molecular dispersion of fesoterodine
CA2397942C (en) Controlled release pharmaceutical composition containing tramadol hydrochloride and method for its preparation
CZ20013186A3 (cs) Tableta
SI21256A (sl) Stabilizacija profila sproščanja učinkovin iz formulacije
SK279927B6 (sk) Orálne pevné farmaceutické prípravky obsahujúce ge
KR20230096434A (ko) 콜린알포세레이트를 포함하는 약학 제제
Nada et al. Effect of raw materials on the formulation of norfloxacin tablets

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20120830